abstract |
The present disclosure relates to the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to particular dosage regimens for the administration of ADCs which bind to CD19 (CD19-ADCs). |